Article
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Proceedings of the National Academy of Sciences of the United States of America - 15 Oct 2013
Johnson Neil, Johnson Shawn F, Yao Wei, Li Yu-Chen, Choi Young-Eun, Bernhardy Andrea J, Wang Yifan, Capelletti Marzia, Sarosiek Kristopher A, Moreau Lisa A, Chowdhury Dipanjan, Wickramanayake Anneka, Harrell Maria I, Liu Joyce F, D'Andrea Alan D, Miron Alexander, Swisher Elizabeth M, Shapiro Geoffrey I
Abstract excerpt
Breast Cancer Type 1 Susceptibility Protein (BRCA1)-deficient cells have compromised DNA repair and are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. Despite initial responses, the development of resistance limits clinical efficacy. Mutations in the BRCA C-terminal (BRCT) domain of BRCA1 frequently create protein products unable to fold that are subject to protease-mediated degradation. Here, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.